Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept Dosing Regimens in AMD
NCT01824225Phase 4Completed
- Sponsor
- Nihon University
- Start
- Mar 2013
- Primary completion
- Mar 2014
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in age-related macular degeneration (AMD), sponsored by Nihon University. Started Mar 2013; status: completed.
02
Drugs
aflibercept
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT01824225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01824225.